AR023464A1 - NEW NOVELS OF THE OX2 PROTEIN OF MAMMER AND RELATED REAGENTS - Google Patents

NEW NOVELS OF THE OX2 PROTEIN OF MAMMER AND RELATED REAGENTS

Info

Publication number
AR023464A1
AR023464A1 ARP000101685A ARP000101685A AR023464A1 AR 023464 A1 AR023464 A1 AR 023464A1 AR P000101685 A ARP000101685 A AR P000101685A AR P000101685 A ARP000101685 A AR P000101685A AR 023464 A1 AR023464 A1 AR 023464A1
Authority
AR
Argentina
Prior art keywords
mammer
novels
protein
new
related reagents
Prior art date
Application number
ARP000101685A
Other languages
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR023464A1 publication Critical patent/AR023464A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)

Abstract

Composiciones y métodos para utilizar OX2 de ligando de mamífero para tratar una condicion fisiologica anormal en un individuo. Los métodos comprendenadministrar una cantidad terapéuticamente efectiva de OX2 sola, o en combinacion con otrosreactivos terapéuticos; o un antagonista de OX2.Compositions and methods for using mammalian ligand OX2 to treat an abnormal physiological condition in an individual. The methods comprise administering a therapeutically effective amount of OX2 alone, or in combination with other therapeutic reagents; or an OX2 antagonist.

ARP000101685A 1999-04-13 2000-04-12 NEW NOVELS OF THE OX2 PROTEIN OF MAMMER AND RELATED REAGENTS AR023464A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29082599A 1999-04-13 1999-04-13

Publications (1)

Publication Number Publication Date
AR023464A1 true AR023464A1 (en) 2002-09-04

Family

ID=23117713

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101685A AR023464A1 (en) 1999-04-13 2000-04-12 NEW NOVELS OF THE OX2 PROTEIN OF MAMMER AND RELATED REAGENTS

Country Status (7)

Country Link
EP (1) EP1171154A2 (en)
JP (1) JP2002541210A (en)
AR (1) AR023464A1 (en)
AU (1) AU4341300A (en)
CA (1) CA2369454A1 (en)
MX (1) MXPA01010480A (en)
WO (1) WO2000061171A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4381140B2 (en) 2001-10-12 2009-12-09 シェーリング コーポレイション Use of bispecific antibodies to modulate the immune response
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
GB202115803D0 (en) 2021-11-03 2021-12-15 Ducentis Biotherapeutics Ltd Novel proteins
WO2023214387A1 (en) 2022-05-06 2023-11-09 Ducentis Biotherapeutics Limited Novel cd200 fusion proteins
WO2023214388A1 (en) 2022-05-06 2023-11-09 Ducentis Biotherapeutics Limited Novel cd200 fusion proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859208A (en) * 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
WO1997021450A1 (en) * 1995-12-08 1997-06-19 Brigham And Women's Hospital, Inc. Ox-2 costimulatory molecule
US5753218A (en) * 1996-05-03 1998-05-19 Schering Corporation Method for treating inflammation
DE69833779T2 (en) * 1997-11-07 2006-11-30 Trillium Therapeutics Inc., Toronto METHOD AND COMPOSITIONS FOR IMMUNOMODULATION

Also Published As

Publication number Publication date
EP1171154A2 (en) 2002-01-16
MXPA01010480A (en) 2002-03-27
WO2000061171A2 (en) 2000-10-19
WO2000061171A9 (en) 2002-01-03
AU4341300A (en) 2000-11-14
JP2002541210A (en) 2002-12-03
CA2369454A1 (en) 2000-10-19
WO2000061171A3 (en) 2001-01-25

Similar Documents

Publication Publication Date Title
AR047841A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNE-INFLAMMATORY DISORDERS
FR13C0062I2 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR TREATING NEUROLOGICAL DISORDERS
CO5011096A1 (en) MEDICINES CONTAINING ANTAGONISTS OF THE 5-HT3 RECEPTOR FOR THE TREATMENT OF IBS
ES2185816T3 (en) FORMS OF PHARMACEUTICAL DOSAGE FOR THE ORAL ROUTE, WHICH INCLUDE AN INHIBITING AGENT OF THE PUMP OF PROTONS AND A PROCEDURAL AGENT.
AR026610A1 (en) A PIRROLIDINACETAMIDE DERIVATIVE ONLY OR IN COMBINATION FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
BR9006924A (en) FORMULATION FOR THE TREATMENT OF SYMPTOMS AND DISEASES, USE OF FORMULATION FOR THE TREATMENT OF SYMPTOMS AND DISEASES, METHOD FOR THE TREATMENT OF SYMPTOMS AND DISEASES, DISTRIBUTION OF MEDICINAL AND THERAPEUTIC AGENTS FOR THE TREATMENT OF SYMPTOMS AND DISEASES IN COMBINATION
TR199901417T2 (en) New compositions with analgesic effect.
TR200100054T2 (en) Paroxetine methanesulfonate
DK0839026T3 (en) Micellar polyether block copolymer compositions for targeting biological agents
AR034213A1 (en) COMPOSITIONS OF DRUGS ON THE BASE OF ANTI-POLINERGIC AGENTS AND INHIBITORS OF PDE-IV
AR034900A1 (en) USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT
SE0002754D0 (en) New pharmaceutical combination formulation and method of treatment with the combination
DK0781281T3 (en) Beta-Carboline derivatives as melatonin agonists, processes for their preparation and their use as a drug
NO20024646L (en) Combination therapies with vasculature-damaging activity
DE69932510D1 (en) VASKULARISIERUNGSINHIBITOREN
BR0215404A (en) process and device for reducing therapeutic dosage
ATE260650T1 (en) ORAL DOSAGE FORMS FOR ADMINISTRATION OF A FIXED COMBINATION OF TRAMADOL AND DICLOFENAC
ES2174337T3 (en) TOPICAL USE OF KAPPA OPIOID AGONISTS FOR THE TREATMENT OF EYE PAIN.
BR0113165A (en) 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods
FI962550A (en) Deuterated active substances for transdermal use
AR023464A1 (en) NEW NOVELS OF THE OX2 PROTEIN OF MAMMER AND RELATED REAGENTS
UY26171A1 (en) PHARMACEUTICAL FORMULATION AND METHOD FOR THE TREATMENT OF LATE APPEARANCE DYSKINESIA
AR041595A1 (en) THERAPEUTIC TREATMENT
DK1611252T3 (en) In vitro method for detecting transitional cell carcinoma of the bladder
PT862454E (en) NEW USES OF MAMIFERO CTLA-8 AND RELATED REAGENTS

Legal Events

Date Code Title Description
FB Suspension of granting procedure